Renovaro Biosciences Inc. - Common Stock RENB 深 滬
等待開盤 07-18 09:30:00 美东时间
0.3151
-0.024
-7.05%
華盛通- 最 高0.36
- 今 開0.3575
- 成交量 147.30万股
- 最 低 0.3151
- 昨 收 0.339
- 總市值 5419.72万
- 52周最高 2.10
- 市盈率 靜 --
- 換手率 0.86%
- 52周最低 0.264
- 委 比 -9.71%
- 總股本 1.72亿
- 歷史最高 13.78
- 量 比 1.02
- 振 幅 13.24%
- 歷史最低 0.264
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Renovaro Biosciences Announces Publication Of Peer-Reviewed Study In Vaccines; Says Preclinical Data Validate Renovaro's Platform Representing Step Forward In Fight Against Pancreatic And Solid Tumors
Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumorsLOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences
07-17 21:20
Renovaro Biosciences Receives Nasdaq Compliance Notice
Renovaro Biosciences ( ($RENB) ) has shared an announcement. Renovaro Inc. rece...
07-14 21:43
Renovaro's BioSymetrics Unveils Proprietary AI-Based Zebrafish Screening Platform To Identify Medical Countermeasures For Neurotoxic Chemical Agents
Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents,
06-30 21:30
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution...
06-10 23:13
Renovaro Biosciences Subsidiary CEO Resigns Abruptly
Renovaro Biosciences ( ($RENB) ) has issued an update. On May 30, 2025, Maurice...
06-06 04:44
Renovaro shares are trading higher after the company announced its subsidiary, BioSymetrics, received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions"
Renovaro shares are trading higher after the company announced its subsidiary, ...
06-03 22:07
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Renovaro Inc. subsidiary BioSymetrics receives a USPTO patent allowance for "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions." The patent enhances Renovaro's AI/ML IP portfolio by enabling integration and harmonization of diverse biomedical data sources into a standardized framework for predictive modeling. CEO David Weinstein highlights this as a strategic milestone, forming the foundation for an AI-powered drug ...
06-03 13:15
Renovaro Receives Ruling To Expedite Trial In 2025 For Lawsuit It Filed On May 9, 2025, In Delaware Court Of Chancery Against Predictive Oncology Seeking To Enforce Binding Merger Agreement Executed On January 1, 2025
Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025
05-22 23:11
Renovaro Agrees On Terms For Exclusive Collaboration Agreement With Amsterdam UMC To Jointly Evaluate And Develop Blood Platelet RNA Diagnostics
Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with
05-13 21:20
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock moved upwards by 63.1% to $...
04-23 05:05
